Skip to main content

Articles

Page 27 of 33

  1. The cerebrospinal fluid (CSF) biomarkers amyloid-β (Aβ), tau and phosphorylated tau (p-tau181) are now used for the diagnosis of Alzheimer’s disease (AD). Aβ40 is the most abundant Aβ peptide isoform in the CS...

    Authors: Julien Dumurgier, Susanna Schraen, Audrey Gabelle, Olivier Vercruysse, Stéphanie Bombois, Jean-Louis Laplanche, Katell Peoc’h, Bernard Sablonnière, Ksenia V Kastanenka, Constance Delaby, Florence Pasquier, Jacques Touchon, Jacques Hugon, Claire Paquet and Sylvain Lehmann
    Citation: Alzheimer's Research & Therapy 2015 7:30
  2. Dementia with Lewy bodies is an under-recognized disease; it is responsible for up to 20 % of all dementia cases. Accurate diagnosis is essential because the management of dementia with Lewy bodies is more com...

    Authors: Brendon P Boot
    Citation: Alzheimer's Research & Therapy 2015 7:45
  3. Treatment in moderate or severe Alzheimer’s disease (AD) often involves adding memantine to a cholinesterase-inhibitor (ChEI: donepezil, galantamine, rivastigmine). Evidence from six-month randomized trials an...

    Authors: Alireza Atri, Suzanne B Hendrix, Vojislav Pejović, Robert K Hofbauer, John Edwards, José Luis Molinuevo and Stephen M Graham
    Citation: Alzheimer's Research & Therapy 2015 7:28
  4. White matter (WM) magnetic resonance imaging (MRI) hyperintensities are common in Alzheimer’s disease (AD), but their pathophysiological relevance and relationship to genetic factors are unclear. In the presen...

    Authors: Katrin Morgen, Michael Schneider, Lutz Frölich, Heike Tost, Michael M Plichta, Heike Kölsch, Fabian Rakebrandt, Otto Rienhoff, Frank Jessen, Oliver Peters, Holger Jahn, Christian Luckhaus, Michael Hüll, Hermann-Josef Gertz, Johannes Schröder, Harald Hampel…
    Citation: Alzheimer's Research & Therapy 2015 7:27
  5. The objective of this study was to develop a process to maximize the safety and effectiveness of disclosing Positron Emission Tomography (PET) amyloid imaging results to cognitively normal older adults partici...

    Authors: Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy and Jason Karlawish
    Citation: Alzheimer's Research & Therapy 2015 7:26
  6. Recent studies have shown that several strains of transgenic Alzheimer’s disease (AD) mice overexpressing the amyloid precursor protein (APP) have cortical hyperexcitability, and their results have suggested t...

    Authors: Haakon B Nygaard, Adam C Kaufman, Tomoko Sekine-Konno, Linda L Huh, Hilary Going, Samantha J Feldman, Mikhail A Kostylev and Stephen M Strittmatter
    Citation: Alzheimer's Research & Therapy 2015 7:25
  7. There has been a significant increase in the use of testosterone in aging men, but little investigation into its impact on men with Alzheimer’s disease (AD). The findings of the few studies that have been done...

    Authors: James R Hall, April R Wiechmann, Rebecca L Cunningham, Leigh A Johnson, Melissa Edwards, Robert C Barber, Meharvan Singh, Scott Winter and Sid E O’Bryant
    Citation: Alzheimer's Research & Therapy 2015 7:24
  8. CAD106 is designed to stimulate amyloid-β (Aβ)-specific antibody responses while avoiding T-cell autoimmune responses. The CAD106 first-in-human study demonstrated a favorable safety profile and promising anti...

    Authors: Martin R Farlow, Niels Andreasen, Marie-Emmanuelle Riviere, Igor Vostiar, Alessandra Vitaliti, Judit Sovago, Angelika Caputo, Bengt Winblad and Ana Graf
    Citation: Alzheimer's Research & Therapy 2015 7:23
  9. A wide variety of atypical antipsychotic drugs (risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone and clozapine) are widely used in the management of neuropsychiatric symptoms, which are commonly ...

    Authors: Lin Tan, Lan Tan, Hui-Fu Wang, Jun Wang, Chen-Chen Tan, Meng-Shan Tan, Xiang-Fei Meng, Chong Wang and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2015 7:20

    The Retraction Note to this article has been published in Alzheimer's Research & Therapy 2016 8:28

  10. Alzheimer’s disease (AD) is the most common neurodegenerative disorder affecting older people worldwide. It is a progressive disorder mainly characterized by the presence of amyloid-beta (Aβ) plaques and neuro...

    Authors: Peter Thériault, Ayman ElAli and Serge Rivest
    Citation: Alzheimer's Research & Therapy 2015 7:41
  11. Despite significant progress, a disease-modifying therapy for Alzheimer’s disease (AD) has not yet been developed. Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conform...

    Authors: Haakon B Nygaard, Allison F Wagner, Garrett S Bowen, Susan P Good, Martha G MacAvoy, Kurt A Strittmatter, Adam C Kaufman, Brian J Rosenberg, Tomoko Sekine-Konno, Pradeep Varma, Kewei Chen, Anthony J Koleske, Eric M Reiman, Stephen M Strittmatter and Christopher H van Dyck
    Citation: Alzheimer's Research & Therapy 2015 7:35
  12. Studies with strong selection biases propose that alpha-synucleinopathy (AS) spreads upwards and downwards in the neuraxis from the medulla, that amygdala-dominant AS is strongly associated with Alzheimer’s di...

    Authors: Julia Zaccai, Carol Brayne, Fiona E Matthews and Paul G Ince
    Citation: Alzheimer's Research & Therapy 2015 7:19
  13. Marked improvements in survival and health outcome for people infected with HIV have occurred since the advent of combination antiretroviral therapy over a decade ago. Yet HIV-associated neurocognitive disorde...

    Authors: Ronald A Cohen, Talia R Seider and Bradford Navia
    Citation: Alzheimer's Research & Therapy 2015 7:37
  14. Weight loss has been described in 20% to 45% of patients with Alzheimer’s disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, thoug...

    Authors: Erika Droogsma, Dieneke van Asselt, Hanneli Bieze, Nic Veeger and Peter Paul De Deyn
    Citation: Alzheimer's Research & Therapy 2015 7:18
  15. Patients can provide consent to have their clinical records linked to a research register, a process known as consent for contact (C4C). There is evidence about how to engage people with mental illness in C4C,...

    Authors: Dan Robotham, Joanne Evans, Andrew Watson, Iain Perdue, Thomas Craig, Diana Rose and Til Wykes
    Citation: Alzheimer's Research & Therapy 2015 7:15
  16. Dementia prevalence increases with age and Alzheimer’s disease (AD) accounts for up to 75% of cases. However, significant variability and overlap exists in the extent of amyloid-β and Tau pathology in AD and n...

    Authors: Colm Cunningham and Edel Hennessy
    Citation: Alzheimer's Research & Therapy 2015 7:33
  17. Amyloid β-protein oligomers play a key role in Alzheimer’s disease (AD), but well-validated assays that routinely detect them in cerebrospinal fluid (CSF) are just emerging. We sought to confirm and extend a r...

    Authors: Ting Yang, Tiernan T O’Malley, Daniel Kanmert, Jasna Jerecic, Lynn R Zieske, Henrik Zetterberg, Bradley T Hyman, Dominic M Walsh and Dennis J Selkoe
    Citation: Alzheimer's Research & Therapy 2015 7:14
  18. Dementia is a substantial and increasing public health concern. Despite decades of research, a cure or effective preventative treatment for dementia remains elusive. We offer critical review of contemporary de...

    Authors: Craig W Ritchie, Graciela Muniz Terrera and Terence J Quinn
    Citation: Alzheimer's Research & Therapy 2015 7:31
  19. There is a growing body of evidence that subtle deficits in instrumental activities of daily living (IADL) may be present in mild cognitive impairment (MCI). However, it is not clear if there are IADL domains ...

    Authors: Katrin Jekel, Marinella Damian, Carina Wattmo, Lucrezia Hausner, Roger Bullock, Peter J Connelly, Bruno Dubois, Maria Eriksdotter, Michael Ewers, Elmar Graessel, Milica G Kramberger, Emma Law, Patrizia Mecocci, José L Molinuevo, Louise Nygård, Marcel GM Olde-Rikkert…
    Citation: Alzheimer's Research & Therapy 2015 7:17
  20. The goal was to identify which neurochemicals differ in professional athletes with repetitive brain trauma (RBT) when compared to healthy controls using a relatively new technology, in vivo Localized COrrelated S...

    Authors: Alexander P Lin, Saadallah Ramadan, Robert A Stern, Hayden C Box, Christopher J Nowinski, Brian D Ross and Carolyn E Mountford
    Citation: Alzheimer's Research & Therapy 2015 7:13
  21. OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA) was a randomized, double-blind comparison of 13.3 mg/24 h versus 9.5 mg/24 h rivastigmine patch in patients with mild-to-moderate ...

    Authors: José L Molinuevo, Lutz Frölich, George T Grossberg, James E Galvin, Jeffrey L Cummings, Tillmann Krahnke and Christine Strohmaier
    Citation: Alzheimer's Research & Therapy 2015 7:9
  22. Group comparisons demonstrate greater visuospatial and memory deficits and temporoparietal-predominant degeneration on neuroimaging in patients with corticobasal syndrome (CBS) found to have Alzheimer’s diseas...

    Authors: Sharon J Sha, Pia M Ghosh, Suzee E Lee, Chiara Corbetta-Rastelli, Willian J Jagust, John Kornak, Katherine P Rankin, Lea T Grinberg, Harry V Vinters, Mario F Mendez, Dennis W Dickson, William W Seeley, Marilu Gorno-Tempini, Joel Kramer, Bruce L Miller, Adam L Boxer…
    Citation: Alzheimer's Research & Therapy 2015 7:8
  23. The clinical syndrome of heart failure is one of the leading causes of hospitalisation and mortality in older adults. An association between cognitive impairment and heart failure is well described but our und...

    Authors: Jane A Cannon, John JV McMurray and Terry J Quinn
    Citation: Alzheimer's Research & Therapy 2015 7:22
  24. Alzheimer’s disease (AD) is a growing socioeconomic problem worldwide. Early diagnosis and prevention of this devastating disease have become a research priority. Consequently, the identification of clinically...

    Authors: Veer B Gupta, Andrea C Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M Laws, Wei Ling Florence Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S Lance Macaulay, Colin L Masters, Christopher C Rowe, Ashley I Bush and Ralph N Martins
    Citation: Alzheimer's Research & Therapy 2015 7:16
  25. The aim of this study was to investigate the association between visual hallucinations in dementia with Lewy bodies (DLB) and brain perfusion using single-photon emission computed tomography.

    Authors: Camille Heitz, Vincent Noblet, Benjamin Cretin, Nathalie Philippi, Laurent Kremer, Mélanie Stackfleth, Fabrice Hubele, Jean Paul Armspach, Izzie Namer and Frédéric Blanc
    Citation: Alzheimer's Research & Therapy 2015 7:6
  26. Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD). Both NPS have negative effects on cognitive performance and ...

    Authors: Yannick Vermeiren, Debby Van Dam, Tony Aerts, Sebastiaan Engelborghs, Jean-Jacques Martin and Peter P De Deyn
    Citation: Alzheimer's Research & Therapy 2015 7:7
  27. The efficacy of a cholinesterase inhibitor, donepezil, in patients with dementia with Lewy bodies (DLB) was investigated to confirm the superiority over placebo in the 12-week, double-blind phase of this phase...

    Authors: Manabu Ikeda, Etsuro Mori, Kazutaka Matsuo, Masaki Nakagawa and Kenji Kosaka
    Citation: Alzheimer's Research & Therapy 2015 7:4
  28. Scarcity of resources means that difficult choices have to be made about how to use them. Cost-effectiveness evidence provides a way to help decision-makers get ‘best value’ from their resources when choosing ...

    Authors: Martin Knapp
    Citation: Alzheimer's Research & Therapy 2015 7:10
  29. Age-related vascular changes, including blood pressure elevation and cerebral blood flow (CBF) reduction, are associated with cognitive decline and Alzheimer’s disease (AD). Evidence suggests that the relation...

    Authors: Lindsay R Clark, Daniel A Nation, Christina E Wierenga, Katherine J Bangen, Sheena I Dev, David D Shin, Lisa Delano-Wood, Thomas T Liu, Robert A Rissman and Mark W Bondi
    Citation: Alzheimer's Research & Therapy 2015 7:3
  30. Recent research on biomarkers has made possible the diagnosis of pre-dementia and even preclinical Alzheimer’s disease (AD), thus providing the ideal context for prevention. The aim of this study was to invest...

    Authors: Javier Mar, Myriam Soto-Gordoa, Arantzazu Arrospide, Fermín Moreno-Izco and Pablo Martínez-Lage
    Citation: Alzheimer's Research & Therapy 2015 7:2
  31. Longitudinal assessment of cognitive decline in amnestic mild cognitive impairment (aMCI) and Alzheimer’s disease (AD) often involves the use of both informant-based and objective cognitive assessments. As eff...

    Authors: Michael Malek-Ahmadi, Kewei Chen, Kathryn Davis, Christine M Belden, Jessica Powell, Sandra A Jacobson and Marwan N Sabbagh
    Citation: Alzheimer's Research & Therapy 2015 7:1
  32. As the need to develop a successful disease-modifying treatment for Alzheimer’s disease (AD) becomes more urgent, imaging is increasingly used in therapeutic trials. We provide an overview of how the different...

    Authors: David M Cash, Jonathan D Rohrer, Natalie S Ryan, Sebastien Ourselin and Nick C Fox
    Citation: Alzheimer's Research & Therapy 2014 6:87
  33. Electroencephalography (EEG) is a longstanding technique to measure electrical brain activity and thereby an indirect measure of synaptic activity. Synaptic dysfunction accompanies Alzheimer’s disease (AD) and...

    Authors: Elisabeth CW van Straaten, Philip Scheltens, Alida A Gouw and Cornelis J Stam
    Citation: Alzheimer's Research & Therapy 2014 6:86
  34. Many neurodegenerative diseases are characterised by accumulations of misfolded proteins that can colocalise with chaperone proteins (for example, heat shock protein 27 (HSP27)), which might act as modulators ...

    Authors: Xuekai Zhang, Jing Shi, Jinzhou Tian, Andrew C Robinson, Yvonne S Davidson and David M Mann
    Citation: Alzheimer's Research & Therapy 2014 6:78
  35. Excessive daytime sleepiness is a commonly reported problem in dementia with Lewy bodies (DLB). We examined the relationship between nighttime sleep continuity and the propensity to fall asleep during the day ...

    Authors: Tanis J Ferman, Glenn E Smith, Dennis W Dickson, Neill R Graff-Radford, Siong-Chi Lin, Zbigniew Wszolek, Jay A Van Gerpen, Ryan Uitti, David S Knopman, Ronald C Petersen, Joseph E Parisi, Michael H Silber and Bradley F Boeve
    Citation: Alzheimer’s Research & Therapy 2014 6:76
  36. Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) are atypical parkinsonian disorders with fronto-subcortical and posterior cognitive dysfunction as common features. While visual hallucinations a...

    Authors: Michael R Misch, Sara Mitchell, Philip L Francis, Kayla Sherborn, Katayoun Meradje, Alicia A McNeely, Kie Honjo, Jiali Zhao, Christopher JM Scott, Curtis B Caldwell, Lisa Ehrlich, Prathiba Shammi, Bradley J MacIntosh, Juan M Bilbao, Anthony E Lang, Sandra E Black…
    Citation: Alzheimer's Research & Therapy 2014 6:71
  37. Lewy body and Alzheimer-type pathologies often co-exist. Several studies suggest a synergistic relationship between amyloid-β (Aβ) and α-synuclein (α-syn) accumulation. We have explored the relationship betwee...

    Authors: Marta Swirski, J Scott Miners, Rohan de Silva, Tammaryn Lashley, Helen Ling, Janice Holton, Tamas Revesz and Seth Love
    Citation: Alzheimer's Research & Therapy 2014 6:77
  38. Optimal identification of subtle cognitive impairment in the primary care setting requires a very brief tool combining (a) patients’ subjective impairments, (b) cognitive testing, and (c) information from info...

    Authors: Michael M Ehrensperger, Kirsten I Taylor, Manfred Berres, Nancy S Foldi, Myriam Dellenbach, Irene Bopp, Gabriel Gold, Armin von Gunten, Daniel Inglin, René Müri, Brigitte Rüegger, Reto W Kressig and Andreas U Monsch
    Citation: Alzheimer's Research & Therapy 2014 6:69
  39. The spectrum of mixed brain pathologies expands beyond accompanying vascular pathology in brains with Alzheimer’s disease-related pathology. Co-occurrence of neurodegenerative non-Alzheimer’s disease-type prot...

    Authors: Jasmin Rahimi and Gabor G Kovacs
    Citation: Alzheimer’s Research & Therapy 2014 6:82